A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
